The treatment success rate for multidrug-resistant tuberculosis in Brazil is projected to see a modest increase from 61% in 2024 to 63% in 2028. Notably, in 2023, this rate was at 60%, indicating gradual improvement. Year-on-year growth showcases a positive trajectory, with a general annual increase of 1-2%, reflecting ongoing advancements in treatment protocols and healthcare investments. Over the five-year period, the compound annual growth rate (CAGR) stands at approximately 1%.
Future trends to watch for include potential breakthroughs in drug therapies and the impact of Brazil’s healthcare policy reforms on accelerating treatment success rates. Continuous monitoring is essential to ensure sustained progress.
